Search details
1.
Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma.
Int J Mol Sci
; 25(2)2024 Jan 19.
Article
in English
| MEDLINE | ID: mdl-38279258
2.
Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
Hepatology
; 76(2): 330-344, 2022 08.
Article
in English
| MEDLINE | ID: mdl-34897774
3.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Future Oncol
; 19(34): 2277-2289, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37746835
4.
Surgical resection criteria and neoadjuvant therapies for intrahepatic cholangiocarcinoma.
Clin Adv Hematol Oncol
; 21(11): 584-591, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37948594
5.
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Int J Mol Sci
; 24(4)2023 Feb 11.
Article
in English
| MEDLINE | ID: mdl-36835036
6.
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Lancet Oncol
; 22(10): 1468-1482, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34592180
7.
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lancet Oncol
; 21(6): 808-820, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32502443
8.
Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Oncologist
; 25(2): 105-111, 2020 02.
Article
in English
| MEDLINE | ID: mdl-32043797
9.
Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.
Oncologist
; 25(3): 197-202, 2020 03.
Article
in English
| MEDLINE | ID: mdl-32162824
10.
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Oncologist
; 24(9): e930-e942, 2019 09.
Article
in English
| MEDLINE | ID: mdl-30833489
11.
An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice.
Hepatology
; 67(1): 159-170, 2018 01.
Article
in English
| MEDLINE | ID: mdl-28718980
12.
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Cancer
; 121(10): 1645-53, 2015 May 15.
Article
in English
| MEDLINE | ID: mdl-25641763
13.
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
J Hepatol
; 63(4): 896-904, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26071796
14.
Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2.
Carcinogenesis
; 35(11): 2393-403, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25096061
15.
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
Hepatology
; 55(6): 1840-51, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22223166
16.
TKIs beyond immunotherapy predict improved survival in advanced HCC.
J Cancer Res Clin Oncol
; 149(6): 2559-2574, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-35773429
17.
Bridging and downstaging with TACE in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant.
Ann Gastroenterol Surg
; 7(2): 295-305, 2023 Mar.
Article
in English
| MEDLINE | ID: mdl-36998293
18.
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
J Clin Oncol
; 41(9): 1747-1757, 2023 03 20.
Article
in English
| MEDLINE | ID: mdl-36512738
19.
Propagated Circulating Tumor Cells Uncover the Potential Role of NFκB, EMT, and TGFß Signaling Pathways and COP1 in Metastasis.
Cancers (Basel)
; 15(6)2023 Mar 17.
Article
in English
| MEDLINE | ID: mdl-36980717
20.
Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment.
Pharmaceutics
; 14(3)2022 Mar 12.
Article
in English
| MEDLINE | ID: mdl-35336003